,56,57,58 The synergistic oncogenic effect between STK11 inactivation and KRAS activation has been revealed to arise from multifaceted factors involving epigenetic reprogramming, metabolic alterations, shifts in signaling pathway dependencies, and the shaping of an immunologically “cold” tumor microenvironment (TME), all of which have been deeply investigated previously.29 The gene discussed is KRAS; the disease is neoplasm.